[CLSTR]
< Back to situation

[REVISION HISTORY]

Global healthcare and AI hardware regulatory developments

Updated 4 times since CLSTR started tracking revisions of this situation.

What changed

2026-10-06 00:34 UTC → 2026-10-06 14:08 UTC · added removed

Regulatory authorities in India and the United Kingdom are advancing distinct frameworks to address the integration of artificial intelligence into healthcare, pharmaceuticals, and critical hardware sectors. In India, the Drugs Controller General of India (DCGI) Rajeev Raghuvanshi previously expressed concerns regarding accountability and whether AI solutions meet current medical device definitions. Expanding this regulatory scope, Electronics and Information Technology Secretary S. Krishnan indicated that the government is now evaluating stricter oversight for AI-linked hardware and biometric devices. To mitigate security risks from unverified sensors, cameras, and scanners in sectors like manufacturing and agriculture, officials are considering a vetting model similar to the Trusted Telecom Portal to ensure supply chain visibility. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) has moved toward implementing its recommendations for modernizing AI legislation. Following MHRA chief Lawrence Tallon’s observation that current frameworks are ill-equipped for adaptive AI models, the agency The UK government has committed to a system announced it will accept all 44 recommendations from the National Commission into the Regulation of AI in Healthcare. This decision marks a shift toward continuous monitoring for AI-based of AI-enabled medical devices. This approach aims to manage non-deterministic algorithms that evolve during clinical use through ongoing surveillance devices rather than relying solely on one-time pre-approval safety checks. Lawrence Tallon, Chief Executive of the MHRA, noted that the move addresses the complexity of “non-deterministic algorithms” that evolve and adapt during clinical use. To support this, the MHRA is launching the third phase of its “AI Airlock” regulatory sandbox, focusing on post-market surveillance and monitoring devices throughout their entire lifecycle. The UK government intends to publish a full preliminary implementation plan by spring 2027. Additionally, the MHRA has opened applications for the third phase end of its ‘AI Airlock’ program, which will focus specifically on post-market lifecycle monitoring. this year, with a full plan expected by spring 2027 to establish delivery targets across the National Health Service (NHS). In Sweden, a preliminary study by Socialstyrelsen continues to highlight that the healthcare sector lacks sufficient oversight, noting that a CE marking does not guarantee an AI system will function correctly in specific local environments.

Versions

  1. 2026-10-06 14:08 UTC Global healthcare and AI hardware regulatory developments
  2. 2026-10-06 00:34 UTC Global healthcare and AI hardware regulatory developments
  3. 2026-09-17 09:44 UTC Global healthcare AI regulatory challenges
  4. 2026-09-13 14:31 UTC Global healthcare AI regulatory challenges
  5. 2026-09-10 01:38 UTC Global healthcare AI regulatory challenges

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.